Good afternoon, everyone and thank you for joining us today. We at DAM Capital Advisors Limited are pleased to host SRF Limited's Q2 and H1 FY '27 results conference call.

We have with us today Mr. Samir Kashyap, President, Chief Financial Officer and Ms.

Sugandha Singhal, Senior Vice President, Head Treasury and Investor Relations of SRF Limited. Now I'd like to invite Miss Nitika Dhawan, Head of Corporate Communication at SRF to initiate proceedings for the results con-call.

Please go ahead, ma'am.

Good afternoon, everyone and thank you for joining us on SRF Limited's quarter two and half year, FY 2027 results conference call. We will begin this call with brief opening remarks from our President and Chief Financial Officer, Mr.

Samir Kashyap, following which we will open the forum for an interactive question-and-answer session. Before we begin this call, I would like to point out that some statements made in this call may be forward-looking and a disclaimer to this effect has been included in the earnings presentation shared with you earlier.

I would now like to invite Mr. Kashyap to make his opening remarks.

Thank you, Nitika. Good afternoon, everyone, and welcome to SRF Limited's Q2 and H1 FY '27 earnings conference call.

Thank you for joining us today. I trust you've had the opportunity to review our financial results and the investor presentation shared earlier.

I will begin with an overview of our performance for the quarter and the first half of the financial year, and then cover key developments and business updates across our segments, after which we will open the floor for questions. I am pleased to share that SRF delivered a strong performance across its key business segments in Q2 FY '27 despite continuing global uncertainty.

The operating environment remained volatile. Geopolitical developments, supply chain disruptions, higher raw material prices and elevated freight costs, all weighed on the quarter.

However, despite these headwinds, our businesses responded effectively to changing market conditions and remained focused on maximizing opportunities. This was supported by a diversified portfolio, continued focus on operating efficiency, and our strong customer relationships.

We continue to make advances on our strategic investments, technology-led cost optimization interventions, and new product development initiatives. Our investments in future growth areas continue to progress well, laying the foundation for sustainable growth and strengthening our market position.

We remain focused on building our capabilities, deepening customer relationships, and growing the share of value-added products to support the company's growth over time. For the quarter ended September 30th, 2026, consolidated revenue stood at 4,904 crores, registering a growth of 35% when compared with a comparable period last year.

The company's operation EBIT increased by 26% to 816 crores over the comparable period last year, and profit after tax stood at 509 crores, registering a growth of 31% over the corresponding period last year. For H1 FY '27, consolidated revenue increased by 33% to 9,937 crores when compared with the comparable period last year, while operational EBIT grew by 44% to ₹1,932 crores over the comparable period last year.

Profit after tax increased by 55% to 1,268 crores, again when compared with the comparable period last year. At the start of the year, we had guided to a revenue growth of 15% to 20% in our Chemicals Business.

With a strong H1 performance delivered, we feel confident to reiterate that we expect to deliver towards the higher end of the stated guidance for FY '27. I will now take you through the performance of our individual businesses.

Our Chemicals Business reported a 25% increase in revenue from 1,667 crores to 2,079 crores during Q2 FY '27, compared with the corresponding period last year. The Specialty Chemicals Business continued to operate in a challenging market environment.

In agrochemicals, we are witnessing demand recovery across select pockets, underpinned by a strong customer relationships. Progress made by some of our customers on registrations for key active ingredients is further strengthening our future demand visibility.

We compute continue to expand our pharmaceutical intermediates portfolio through targeted product development and customer engagements. New product approvals and commercialization are progressing effectively, and helping us build a broader portfolio and opportunity pipeline.

Together, these developments in agrochemicals and pharmaceuticals are positive for the business. We expect them to ramp up progressively over the coming years.

Launching new products and scaling up existing ones remain key priorities for the business. In an environment shaped by safe capacity, we remain focused on strengthening our cost competitiveness through technology-led process improvements and effective sourcing strategies.

Our ability to export select products even to China, reflects well on the strength of our technology, operational efficiency, and global cost competitiveness. The commentary from global innovators on the proposed diversification of their supply chains away from Europe, is encouraging.

While both China and India are expected to benefit from this shift, many customers continue to value a diversified and resilient supplier base, creating opportunities for trusted Indian manufacturers. We have witnessed similar trends in the past where changes in global supply chains translated into incremental business opportunities for Indian producers.

Given our technology strengths, demonstrated cost competitiveness, and longstanding customer relationships, we believe SRF is well-positioned to participate in this evolving opportunity. Beyond agrochemicals and pharmaceuticals, we are leveraging our chemistry, process innovation, and scale-up capabilities to expand into new domains beyond our traditional areas of strength.

This provides us an opportunity to enter new segments, such as solutions centered around environment and sustainability. At an appropriate juncture, we will share more on these opportunities.

R&D remains a key competitive advantage for SRF and an important enabler of our long-term growth strategy. Our team of over 500 scientists, engineers, and scale-up specialists work through dedicated research labs.

These include separate teams focused on agrochemicals, pharmaceuticals, and other specialty applications. This domain-focused approach has accelerate innovation tailored to specific market requirements.

SRF now has 160 patents and has filed 539 patent applications in total, reflecting our sustained commitment to technology leadership and value creation. The Fluorochemicals Business delivered a strong quarter, demonstrating the strength and operational excellence of the business.

Our growth was supported by higher HFC volumes, improved realizations, and successful expansion into newer markets. Despite disruption to global trade flows and logistics, given the ongoing geopolitical uncertainty, the business could make significant inroads to expand volumes and revenues even in the Middle East.

We have been able to continuously broaden our geographic footprint, gain market share, and leverage our product portfolio to maximize market-specific opportunities. Additionally, sustained domestic leadership and improving returns from our brand investments, further strengthened our competitive position.

The HFC capacity expansion at Dahej is progressing well, and remains aligned with our long-term growth strategy. Our immediate priority continues to be maximizing utilization of the existing HFC plants during the baseline period, while strengthening our presence in key markets and expanding customer relationships.

Looking ahead, we expect demand and pricing for refrigerants to remain broadly stable, barring normal seasonality, while our diversified geographic footprint and continued expansion into newer geographies is expected to support growth and provide greater resilience across specific market cycles. We are also preparing for the next generation of refrigerants through our HFO investment at Gopalpur, Odisha, where key regulatory approvals have recently been secured.

The HFO project is on track for commissioning in Q4 FY '28. On commissioning, we expect to be among the top three to four refrigerant gas manufacturers globally, which will significantly strengthen our competitive position in the industry.

Our in-house HF integration will enable us to address opportunities associated with electronic grade HF, for wafer cleaning in the semiconductor industry. In Fluoropolymers, our focus continues to be on enhancing the grades in our PTFE portfolio.

During the quarter, we made further progress in customer qualifications and commercialization of higher value grades, resulting in an improved product mix led by fine cut grades and the commencement of commercial micropowder sales as well. As we continue to broaden our presence in specialized applications, the portfolio is becoming increasingly differentiated, positioning the business beyond bulk PTFE and improving the business mix to higher value grades over time.

Our PVDF project remains on track for capitalization with customer engagements underway across multiple end-use applications. PVDF will initially start making inroads into chemical processing, fluid handling, and architecture coating applications, with a goal to gradually move to solar and battery applications as well.

This is an important milestone in expanding our fluoropolymer portfolio to address higher growth segments. Our FEP and FKM projects are also progressing well and are on track.

This partnership with Chemours creates a unique opportunity to enter into applications that require high performance, durability, and advanced functionality. The growth in our fluoropolymer portfolio over time will not only expand our addressable market, but will also strengthen our positioning in emerging value chains across electricals and electronics, semiconductors, and aerospace and defense.

Moving on to our performance films and foils business. The business recorded a 51% increase in revenue from 1,408 crores to 2,122 crores during Q2 FY '27, compared to the corresponding period last year.

The performance films and foils business continues to perform well in a challenging operating environment. Even as customer procurement patterns moderated during the quarter, following elevated buying activity in Q1, demand remained robust across geographies and asset utilization stayed strong.

While elevated raw material prices in the quarter led to a moderation in inventory-related benefits, compared with the previous quarter, the business continued to deliver healthy growth through disciplined execution and a growing contribution from value-added products. Our focus remains on expanding our portfolio of value-added products and differentiated substrates that are aligned with long-term growth sectors and evolving customer requirements.

These continued to gain traction, led by offline-coated and metallized products across geographies. Capacitor-grade film has scaled up well, with key customer approvals having been secured and commercial sales progressing well ahead of initially anticipated timelines, enabling us to participate in the fast-growing electrical and electronics sector.

This is complimented with the progress we have made on securing approvals from key customers for aluminum foil used in capacitors, where commercial sales are expected to commence in Q3 of FY '27. On the operational front, the hybrid BOPP-BOPE film line is expected to commercialize in Q3 of FY '27.

Sustainability continues to be an important strategic priority for the business. We are actively working with customers and partners to develop solutions that support circularity, including recyclable mono-material structures, advanced coatings, and sustainable packaging formats.

These initiatives respond to changing customer and regulatory requirements, while supporting the development of differentiated solutions. R&D continues to drive our shift towards value-added films and foil.

We have commercialized 16 products across BOPET, BOPP, and CPP, including 13 offline coatings, and more than 35 products are under development. We are amongst the forerunners in the industry in super ultra-high barrier across substrates.

We are also building sustainable mono-material solutions using BOPE, BOPLA, and BOPA, supported by 17 R&D collaborations with leading global brand owners. Our aluminum foils business delivered a strong financial performance and is steadily evolving into an important growth area.

This has been supported by strengthening export traction and successful advancement into higher value grades. We have made considerable progress on high-end aseptic packaging and are now working closely with one of the global leaders in this space.

These developments have collectively enabled the business to transition from being a pure packaging films player to a high-end performance films and foils business. Moving on to our Technical Textiles Business.

The business reported a 25% increase in revenue from 474 crores to 594 crores during Q2 FY '27 over the comparable period last year. The Technical Textiles Business maintained healthy momentum during the quarter.

In tyre cord fabrics, we continue to make steady progress in the scale up of N66 and polyester tyre cord fabrics, with customer approvals being positive developments for the business. The upcoming dipping capacities is expected to further enhance the product mix and capacity utilization in coming quarters.

Belting fabrics delivered another strong quarter, benefiting from export growth and continued customer additions. Alongside this, we expanded our value-added portfolio through new product commercialization and customer qualifications.

We expect the business to remain stable, supported by export markets and a growing contribution from higher value applications. Our other businesses comprising coated fabrics and laminated fabrics also delivered a stable performance during the quarter.

The coated fabrics business maintained its leadership position in the domestic market, supported by a healthy product mix and continued emphasis on value-added products. Our focus on operational efficiencies and cost optimization helped us navigate the competitive pressures well.

The laminated fabrics business delivered a steady performance supported by stable demand across its key applications. Recognizing the immense opportunity presented across a set of identified sunrise sectors, SRF has embarked on a journey to effectively target these high-growth areas where our growing product portfolio has wide applications.

These identified high-priority sectors span energy storage, electricals and electronics, semiconductors, next generation cooling solutions, environment, sustainability and renewables, and aerospace and defense. A detailed map on how our new product portfolio addresses specific applications in each of these sunrise sectors is part of our investor presentation.

While many of these are already announced investments, I would like to draw your attention to the new capex that was approved around aluminum foil for battery applications to address the growing opportunities in the energy storage and EV sectors. You would recollect that over a year ago, we had rebranded our packaging films business to a performance films and foils business, to reflect our growing aspirations in this segment.

In an important step towards realizing these growth aspirations, as already had intimated yesterday, our board has approved an investment of approximately ₹600 crores to set up a new aluminum foil facility at our existing site at Jhatpat in Madhya Pradesh, to cater to battery applications targeted at the growing energy storage and EV sectors. The facility will have a total capacity of about 12,000 metric tons per annum, and will serve both lithium-ion and sodium-ion battery applications, along with high-end packaging foil.

The project will be carried out in two phases. Phase one has an estimated cost of ₹300 crores and is expected to be completed within about 23 months of the board approval.

Importantly, the proposed universal foil mill shall be capable of producing both battery-grade and high-end packaging foil. This provides us operational flexibility, enabling us to address multiple value-added end-use markets, even while customer qualifications for battery applications are in progress.

This investment is an important step in expanding our foil business to address battery applications with growing demand arising from the energy storage and EV sectors. The government's ACC PLI scheme, which incentivizes domestic battery manufacturing and mandates progressive domestic value addition, is also expected to accelerate localization of the battery supply chain, driving demand for key materials, including battery-grade aluminum foil.

During Q2 FY '27, SRF Foundation continued to create meaningful impact across education, digital learning, STEM, skilling, health and community development. From strengthening teacher capabilities and advancing AI, robotics, and digital literacy, to promoting student innovation, vocational skills, and community participation, the quarter saw several initiatives translate learning into real-world opportunities.

Recognition for students across innovation and sports platforms further reflected the growing impact of these interventions in empowering young people and communities. During the quarter, I'm happy to share that SRF was recognized as the overall winner in the Best Supply Chain Solution category at the Adam Smith Awards Asia 2026, recognizing our work in building financial resilience across our supply chain.

We also received the Supplier Collaboration and Innovation Award at the UBS Forums' Procurement Excellence Summit & Awards in 2026, recognizing our focus on innovation and collaboration with our suppliers. These awards reaffirm SRF's commitment to operational excellence, strategic planning, and innovation across businesses.

In closing, I would like to state that despite a volatile environment, we remain confident of delivering a healthy second half. Our resilient business models are delivering on the outcomes we had envisaged, and with our investments that target specific sunrise sector opportunities, I'm confident that the future of the company is on a strong wicket.

On that note, I conclude my remarks and will be glad to discuss any questions that you may have. I would now like to ask the moderator to open the line for the Q&A session.

Thank you very much.

Thank you very much. We will now begin with the question and answer session.

Anyone who wishes to ask a question may press star and one on the touchtone telephone. If you wish to remove yourself from the question queue, you may press star and two.

Participants are requested to use handsets while asking a question. Participants, in order to ensure that the management is able to address questions from all participants in the conference, please limit your questions to two per participant.

Ladies and gentlemen, we will wait for a moment while the question queue assembles. The first question is from the line of Rohit Nagraj from 360 ONE Capital Market Private Limited.

Please go ahead.

Hi. Good afternoon.

Thanks for the opportunity. Sir, first question is, you just mentioned in your opening remarks that second half seasonally is the best for us and we're confident that our growth will be more in second half.

Is it backed by certain firm commitments, particularly in the Chemicals Business and an allied question to that, in terms of the AI commercialization, the six seven which we have been working on, if you can give the latest update on the same? Thank you.

Thanks for your question, Rohit. What I had reiterated was that on our overall guidance for the year on CB revenue, we remain firm that we should be able to land at the higher end of that range.

In terms of H2 specifically, yeah, we do see a good ramp on specialty from where we are at this point. I think even last quarter, we talked about the fact that we're starting to see volume recovery.

On the revenue front, I do think we'll see a stronger second half for specialty specifically. In terms of the AI, what we called out on the investor presentation as well, is that on a couple of the products, two specifically, we've had customers make progress in terms of their own registrations.

If this is in a couple of initial markets, and that should in due course start translating into better visibility in terms of our own funnel in terms of us supplies into them.

Thanks a lot, sir. Sir, second question is, what would be our marketing strategy for HFOs once we commercialize at the end of FY '28?

Is it going to be domestic or exports market and there too whether we have certain firm commitments from certain geographies or customers? Thank you.

Yes, sir. The HFO play, at least in the initial couple of years, is purely going to be largely Western World-oriented.

I think that that's a certainty. I think the fact that as a company, we have operated in those markets for the number of years that we have already, positions us very well in terms of already being entrenched with the whole distribution system over there, as well as customer base.

There will be some incremental efforts, I think from a marketing standpoint, but I think we've already established ourselves very well in those markets even in the past, and then, therefore, I think it should not be a significant transition or significant incremental investment to start addressing that opportunity area as HFOs come on stream.

Thanks a lot and all the best, sir.

Thank you.

Thank you. The next question is from the line of Arjun Khanna from Kotak Mahindra Asset Management Company.

Please go ahead.

Thank you, sir, for taking my question. The first question is on the HFC side of things.

What capacity do we envisage during the end of this baseline period? By the end of this quarter what would be our capacity for HFCs?

I think we shared in the last call, Arjun, where we desire to land on capacity. We talked about where our HFC capacity would expand to.

You heard me in my commentary as well, talk about the fact that the incremental portion that has to happen out of Dahej is progressing effectively. I think for fairly obvious reasons as we lead up into the last two months of the baseline period, I'd rather not be very specific about a number where we should land, but I think suffice to say we are progressing very well in terms of the numbers that we called out.

Okay. Sure.

We had talked of the repurposing of some facilities and brownfield expansion. Has that been done or do you expect that to be done by the end of this quarter?

If you're talking about what we were doing in Dahej, like I just said, it's progressing well, and we should be at the level we need to be well in time.

Sure. The second one is on the Chemours projects.

In the previous quarter we said that there was maybe a quarter delay. Would we expect in FY '28 by the first quarter commercialization and in terms of scale up, if you could help us understand, over what period we should see the scale up of this project?

We have said the first of the plants actually would be up on the first product in Q4 of this fiscal and the second one in Q1 of the following fiscal. Those timelines still hold, Arjun.

I think we had also in the previous call, and I reiterate that same comment, I think for it to be at full-scale ramp-up, is probably anywhere between a 10 to 12 months window. Following year after that, is kind of when I think you should see full-stream revenue associated with the Chemours project.

FY '29 we should see the full revenue scale up.

'28, '29. Yeah.

'28, '29, from the start of that year, is kind of reasonable to work with.

Sure. Just a quick one on the capex that we have announced.

In terms of technology, etc., could you help us how is it different from our current aluminum foil project? Because this project, we took slightly longer to scale up.

What are the execution, etc., issues that you envisage out here? In terms of customers, while thank you for the presentation, we have well covered it, but if you could help us in terms of grades, etc., how long would qualifications take?

A great question. I think it's probably best we talk a little bit of the scale-up that we've seen in the aluminum foils business.

That will, I think give you a better picture of how we find ourselves better positioned than maybe where we were say about a year ago. You heard me call this out in the previous call as well, that we are, even in the existing plant, able to move to significantly higher grades.

Conversations have progressed very well with one of the leading aseptic players. That's pretty much the top of the value chain that you're talking about.

These are the likes of Tetra Pak. We are kind of done with audits at our plant as well.

I think a lot of the learnings, yes, you're absolutely right that the scale-up did take some time, but I think we find ourselves in a place where a lot of those learnings are now translating into results, and sharing this progress that we've made on aseptic, I think is a great qualifying benchmark to know that we kind of I almost want to say cracked the code in terms of what we need to do to deliver those higher-end grades. That's kind of where we are drawing a lot of assurance from in terms of our ability to now go further up that chain into battery foil.

It is a different plant in terms of the rolling mill, vis-à-vis what we have today. However, that mill, and I call this out in my opening comments as well, it is going to be a universal mill that can address packaging needs as well.

When you think about higher grades like aseptic, we can use that mill to address a lot of aseptic demand, besides other high grades, even as qualifications around battery continue. Timeline for battery qualification, I think realistically, it's probably anywhere close to a two-year period, from the time we're kind of ready.

In the interim, I think the fact that we've taken this decision to go with the universal mill positions us well to say to use all of what we can produce out of that mill into areas like aseptic and other higher value added grades while qualifications continue, and then we will be able to switch over into battery foil.

Sure. Just for an understanding, would our aluminum foil business possibly by the end of the year be profitable by itself?

I think it's fair to say that.

Sure. Fair.

Thank you and wishing you all the [best?] [unclear].

Just to clarify, in terms of an exit, yeah, absolutely.

Sure. Thank you.

Wishing you all the best.

All right. Thanks, Arjun.

Thank you. The next question is from the line of Kumar Kumar from Ambit Capital Private Limited.

Please go ahead.

Hi, sir. Good afternoon.

Sir, couple of questions from my side.

First

is on the Specialty Chemicals. If you could throw some light on how are the customer engagements and conversations shaping up, given that we are looking at inflationary crop prices and how are they talking about their registration timelines?

I think I answered that just a bit earlier. At least in terms of registration timelines, I just shared I think it was two questions ago.

Compared to when we took this call last quarter and now, there has been progress on at least two of the products. Registrations, like I said, that have progressed, markets like Brazil, a couple of other initial markets.

Finally there seems to be momentum from this long pause I think that we've had waiting. I think we are in a much more positive place to know that at least on two of the products there is momentum.

There is a lag associated between when those registrations happen and when it starts translating into full-blown demand coming through to us. In the interim period, I think it's reasonable to expect that intermediate products that will still be needed, kind of get sourced from us, even as demand around the core AI product itself scales up over a period of time.

That's I think the progress around AI. I'm not sure if I answered your question entirely or if I missed any part.

No, sir. That was clear enough.

Sir, secondly on the aluminum foil project that we have announced, 12,000 ton capacity.

Sir,

typically what is the revenue potential of this project?

Let me answer that question in a different fashion rather than talk about revenue potential. If you think about the price points at which aluminum foil typically sells at, I think you can apply a factor very easily of about one 1.5 times, if not more, around aluminum foil.

You have prices I'm sure available. You can extrapolate from there.

It's a significant uptick vis-a-vis plain-rolled aluminum foil that goes into packaging. Aseptic is about a markup of about 30% 40%.

This goes significantly north even of that.

Got it. In terms of margins, is it fair to assume 15% margin should be achievable in this segment?

We don't guide to that as but just if you look at what I just shared with you in terms of pricing and you look at existing all-tech business and where we kind of exit for this year, I think you would have a good ability to project out what potential margins we could be looking at.

Got it. Sir, lastly if you could just throw some light on the HFO project.

Currently the prices are somewhere $50 to $60. How do you expect this pricing to land up when the patents go off?

I think it's only fair to say that just like what we've seen even in past versions of the generation of refrigerants, there will be a decline when these products come on stream. Having said that, I think what's also important to consume is that the baseline kind of resets in terms of where the price of product is.

We should assume very easily that HFO prices would be at a significant premium versus anything that we see on the HFC side. We're still two years out.

Giving you a specific range is probably premature at this point, but yeah, I think it's very fair to say we should expect a drop off post the product coming off patent, but we should see price points significantly north of typical HFC pricing.

Got it. Thank you, sir.

That was very helpful. Thank you.

All right. Thank you.

Thank you. The next question is from the line of Arun Prasath from Avendus Park Private Limited.

Please go ahead.

Yeah. Thank you for the opportunity.

Good afternoon Samir. First question is on the first half we have grown roughly around 25% YoY on the Chemicals Business.

If you can qualify this growth into the volume and pricing and rupee depreciation will be very helpful.

Arun, we don't split at that level. Yeah.

I can only tell you, prices have stayed firm on the ref gas side. I can also tell you volumes have looked good on ref gas.

Volumes on specialty continue to hold versus kind of where we saw Q1 at. I shared with you even in Q1, we were starting to see green shoots.

Those continue to look better and greener and I think as we walk into the second half of the year, I feel reasonably confident that we'll see a significant growth in specialty revenues driven by better volumes between H2 and H1. That's as much color as I can give you around how pricing and volume is behaving.

Refrigerant prices have stayed strong as well, just in case I didn't share that earlier.

Right. No, no.

Very helpful. Just that how much of this is influence or rupee depreciation has helped us in delivering this first half because now we have fairly in terms of other markets or other producing countries, our currency movement should be helpful in either gaining market share or a rising benefit.

If rupee were to again appreciate back to say 3% 4% 5%, should we see some kind of a reversal in this trend that we have delivered in this first half?

I think a good way to consume our outcome for Q2, Arun, is there's been significant move in the currency even between the two quarters. The fact that Q2 volumes continue to hold good and strong, is a good sign that, and pricing, like I said, is holding.

I think are all good benchmarks to give you a sense that irrespective of currency movement, yeah, I think you've heard our commentary for some time saying we expect prices to stay stable. If you're alluding to could we start seeing softness in price because of competition, import, etc., we don't see that at this point in time.

I think our view on ref gas through the year, we continue to hold that view. What I shared even in the last quarter is we see it being firm, we see strong growth, we see pricing holding.

I think you could see just and that's more a function I think just around what's happening on freight and some input costs. You could see a bit of impact in terms of the cost side of the whole equation, but aside from that, I think we are on a very firm wicket and continue to go from strength to strength.

Understood. Second question is on the semiconductor chemicals.

We have written that into products the product sampling and optimal fixes underway. Are these samples pilot plant or commercial plant and if we can also help us understand what are the series of next steps that we should expect, milestone that you need to do before recording a significant revenue from this segment?

Okay. These are in a commercial plant, but just to give you a little bit more color, in terms of the sampling, a lot of this right now is at the lab level, external to SRF, but at the lab level.

Kind of once you're done with optimization that is necessary, is when I think you should start seeing more commentary from us around more the downstream side of the whole sales chain starting from sampling with customers and qualification. We're a little bit away from that just yet, but I think, the way we've kind of called this slide out, you'll continue to see more and more color from us as we make progress on this journey.

Presently, a lot of it is around lab sampling and our own product optimization as a consequence of what we're hearing back. I don't think we're too far away from starting opening the doors around the customer side conversations.

A lot of pre-work in anyways happening on that front so that we can trigger those pieces once a lot of the product optimization side is done and behind us.

Understood. Thanks Samir.

I'll get back to the queue.

Thank you. The next question is from the line of Ankur Periwal from Axis Capital Limited.

Please go ahead.

Yeah. Hi, sir.

Thanks for the opportunity. First question on the overall pricing environment.

You did allude towards saying that prices are largely stable. Will it be true across spec chem as well as the overall chemicals portfolio, given that there has been a decline in our margins on Q-on-Q basis?

What timeframe are we looking at in terms of full pass through if at all it's a work in progress right now?

Ladies and gentlemen, we have lost the connection for the management. Give us a minute while we have the management online.

Thank you for your patience. We have the management online again with us.

Sir, you may proceed.

My apologies that we dropped. Happy to take the next question.

Thank you. Yes, sir.

Sure. You may proceed.

Sure. I'll just repeat my question.

Maybe it was not heard there. First question was on the RM scenario overall.

You did allude towards largely stable pricing across the segment on a Q-on-Q basis, while we are still seeing a decline in chemicals margins. Just trying to

Sorry to interrupt, Mr. Periwal.

Sir, could you try speaking loudly?

Sorry. Am I audible now?

Yes, sir. Please go ahead.

We can hear you Ankur. Thank you.

Sure. On the pricing front, how are we seeing things there, given that while you said that RM pricing is largely stable, but on the margins front, we are seeing some decline in our chemicals margins on a Q-on-Q basis.

If we could share some No, no,

yeah, just to clarify, I actually said we are seeing pressure on raw material pricing. I think we've been able to offset large parts of that in the businesses either through pass-through to customers or being offset versus our own cost optimization.

Yes, there is pressure on RM pricing. I think everything downstream in petrol as well as on some of the chemicals, there is impact.

That's well known. I think what we've additionally been able to do on some specific inputs, is to be able to secure longer-term contracts with more fixed pricing.

We're not as exposed to the vagaries of price shifts. Is there no impact, that would not be accurate to call out.

There has been some. We're hoping that it kind of stabilizes and gets better from here, but yeah, between quarter-on-quarter, there has been some impact both on raw material, I think, as well as freight.

You probably are well aware of this. Those numbers are significantly higher and elevated.

All of these are having impact at an overall level in terms of margins.

Sure, sir. Just a clarification, the pass through here is we are just specifically talking of specialty chemicals, or even in ref gas there is a lag?

Like I said, I think on the ref gas side the ability to pass things through is looking better. Specialty, I think you all know the commentary from the past.

Every quarter, I think in recent times, we've been talking about volume recovery, price just about starting to look better. The ability, I think over there to pass everything through isn't as much.

However, I would balance that comment out by saying a lot more on the operational efficiency side around the specialty business has helped offset a reasonably large part of the increases, but not entirely.

That's helpful, sir. Just secondly on the packaging films as well as the technical textile margin profile, there were some inventory led gains in the first quarter.

Q2 will be a clean quarter that ways, and how do you see that number sustaining going ahead?

I think it's fair to say on technical textiles, I think there aren't any of those anomalies which were there in the Q1 numbers. On films, I think for the most part, it's kind of normalized.

There was a little bit, I think in dribs, we've had a few situations where pricing kind of moved interestingly. It's a small part, I think of the overall, I think it's reasonably fair to say this is very representative.

Sure, sir. That's it from my side.

Thank you, and all the best.

Yeah. Thanks, Ankur.

Thank you. The next question is from the line of Saurabh Jain from HSBC Asset Management Company.

Please go ahead.

Hi. Thank you for the opportunity.

Continuing on the same question, the Q2 margins have kind of dipped significantly and you explained some reasons also. How to now look at the second half?

Do you think there will be a better pass through in terms of the cost which are likely to remain elevated as we have moved already into 3Q? Or do you see if the margins are going to improve from what we delivered on Q2, going back to 28% 30% kind of margins in the Chemicals Business in particular?

I think that there are lots of factors at play over here, Saurabh. One is obviously how volumes behave.

Like I said, I think let me split it up. Let me answer differently.

If you split it up, I think if you look at the ref gas side, I think over there, pricing for the most part should kind of hold. Whatever little bit of impact there has been in terms of margins on the ref gas side because of elevated input costs, including logistics, transportation, etc., those will probably hold till they kind of wear off.

I think Q2 is reasonably representative in terms of how we look at things forward. I think on the specialty side, as our volumes kind of peak, we will start operating with a much higher level of efficiency as well.

We see a strong ramp coming through now, I think, in terms of revenue side. How much of that starts trickling down through into an EBIT and margin level, wait to be seen.

I don't want to declare victory over here just yet. I think at this point, we derive a lot of confidence from the fact that revenue is looking significantly more positive.

You've always heard us talk about this line around holding share and I think that's now starting to come back and show us early signs of recovery. I think as we get through the second half, you should expect to see that.

How much of that will translate all the way through into margins is given how uncertain things are around the whole geopolitical environment and input costs, it's a little tough and premature to call that out at this point. I think suffice to say we remain optimistic that pricing vis-à-vis customers would reasonably hold and probably get better from here.

On the other hand, if input prices continue to go crazy, how much of that can get passed through is still a question mark, I think.

Sure, that is helpful. Secondly, you also mentioned that the volumes in your HFCs is continuing to going to expand.

Is that more like a mid to long-term comment or even in the near-term you would expect the volumes to expand? If you could also give us some sense in terms of how is the capacity utilizations for you for the HFC portfolio in particular?

I think there's absolutely no doubt anyone should carry that at least through till December of this year, our plan is to run absolutely flat out. That's imperative to maximize on everything that gets locked in in the baseline period.

We called that out specifically. That remains a core focus area.

That should give you adequate sense in terms of capacity utilization. I think they are very, very maximized at this point in time.

Having said that, and I've said this in the past as well, because of the fact that we have a whole stack of products already in the ref gas space, there will be times when we need to optimize what we are even manufacturing in the plant so that we optimize quota. Right?

At the end of the day, that is what everyone's trying to seek to maximize and achieve as we hit December 31st. That will drive a lot of short-term decision-making, but I think you should drive enough assurance and confidence that plants are pretty much maxed out and optimized at this point in time.

That should continue to stay pretty much the way we run the business through all of the next year as well. There's been interesting demand movements.

I'll answer this question a bit differently for you. There've been interesting demand movements even through the first half of the year, between Western World, Asia, and as well as the Middle East, and I think the agility and nimbleness that we've demonstrated to kind of operate across these markets and continue to maximize our outcome, even as demand had looked very different across these geographies, I think just speaks volumes on our ability to not have overdependence on either a specific product or a specific geography.

I think that positions us very uniquely and well in terms of even how things look post December of this year.

Got it. If I may squeeze in one last question if you can give us more color on that side.

For the new projects that you have listed out in the presentation, you talk about it's a billion dollar kind of an opportunity. Is it possible for you to give us some sort of breakdown in terms of how you add up to that $1 billion kind of a number across these different segments?

That can be really useful for us. It's I

I think it's even if you look at the next slide in terms of where we talked about progress, Saurabh, I think, no rocket science saying there that it's clearly at different stages of germination at this point in time. Capacitor, for instance, like I said, we've already commercialized, we're selling, it's at a significant premium to vanilla film.

That's one that's way ahead of the curve versus anything else probably over here. Foil, will come.

I've given you an indication in terms of where price points are likely to be versus, classic foil for packaging, you can do a bit of a math. We've said we're going to do this in phases, phase one will be about half of the total capacity that we've talked about.

Just given where I think battery demand is going to be at, around the time that we're ready, I think we fairly to say fairly safe to say that, when you're kind of have qualified and got to outcomes with customers, you should pretty much be in a place where a lot of that capacity will will kind of get consumed very, very quickly given where both storage and EV is going to be in the country at that point in time, by by any metric, order of magnitude. Many of the others, I think are, they they are still even based on some of the questions that came earlier, are they drawing board where at lab testing.

We are in those stages, I think what we can what we can conclude in in terms of giving you more visibility on this is as you see pro as we see projects kind of get to stage of commercializing, I think that's the place and time where we'll be able to talk numbers more effectively with you. Suffice to say we kind of cumulate this all, that's where we see the opportunity at for us, and this is only These slides right now only talking about places where we have already made inroads.

What I can incrementally tell you, there are at least a couple of other spaces across these sectors itself where in the coming quarters you'll continue to hear more announcements from us in terms of progress made. I can't be more specific than that for obvious reasons, but yeah, there are there are pieces over here that are not even talked about, that still add up to that billion dollar opportunity as we see it.

Right? To split this down at any level at this point in time is very, very premature.

Got it. Thank you so much and all the best.

Thank you so much, Saurabh.

Thank you. The next question is from the line of Surya Narayan Patra from PhillipCapital India Private Limited.

Please go ahead.

Thanks. Thanks for the opportunity, sir.

My first question is about again the sunrise sectors. You have very well packaged your existing manufacturing capacities for the newest industry applications.

Here, we have already indicated about the individual projects and the capex, but going ahead, what would be your kind of a capital allocation towards this? Whether sizeable investment that we are thinking about currently or any color on that and scale up also timeline even if we are thinking about '29, FY '30 like that timeline.

If you can give some color about the timeline possibilities and the kind of a capital allocation that we are talking about the sunrise sectors.

Just like I answered in the previous question, and I think it should be fairly obvious to you both from the slide as well as my earlier commentary, the timelines around how each of these are going to scale and develop is going to be fairly varied, right? Just like I said, capacitor, for instance, is already up there.

Will we invest more? I think just given the traction we've already seen in less than six months, I'm reasonably certain that sooner than later we'll probably plan a second line, right?

We have an approval for it already. I can't tell you with assurance when that will be, but I'm reasonably certain that will happen sooner than later.

You've already seen us talk about our aspiration on foil. We've taken approval from the board for the whole aspiration, right, for all of 600 crores, and then plan this in, go in phases.

That's the level of confidence I think we are approaching some of these. On some of the others, we already made the investment, but, for instance, if you start thinking, and I'll be specific and just call out one example to tell you why I don't think we can give you a number so definitively just at this point.

You look at PVDF and I think it's going to be a journey for us as we kind of go from more entry-level applications all the way through to, say the battery binders space, which will be the highest end grade. Would we need to make more investments between now and getting to that end product grade?

Reasonably certain, yes. What timeline do we contemplate that?

It will be a function I think of how we start seeing offtake in terms of the earlier grades of the product that we produce in the plant, and consequently how we derive more confidence to go and make those investments. I think you have to consume this a little bit as a journey, and like I said and committed to you, you should continue to see more color.

As we go through quarters, I think our commitment is to keep sharing with you proactively as we kind of reach more decisions and are more affirmative on specific steps in terms of incremental capex, etc., if needed.

Sure, sir. My next point is about the HFO project.

See, we know that the timeline and since sometime that we know the timeline about execution and kind of commissioning of the project. In that side, sir, can you give some sense, what are the kind of immediate opportunities that we would be targeting, whether it is a kind of a contact manufacturing kind of thing or what?

Also what challenges that you might face once it is open for kind of suppliers and all that? There also, if you can talk something about the timeline for ramp

up. I think we've always said that our view, and this is not just about HFO, I think we've kind of said this consistently in the past.

The moment anyone is setting up a new plant, I think realistically, SRF's view is, you need a period of somewhere between 8 and 12 months to kind of stabilize and run that plant effectively. You could have some volumes that come out prior to that, but it's not going to be meaningful.

Everything meaningful is about 10 to 12 months away. If you work with a February '28 kind of timeline, which is what we announced around when HFO would be ready, and plan 10 to 12 months from there, that gives you a window to when you should be looking at reasonably larger volumes in terms of revenue on HFO coming out.

What are the challenges, right? I think it should be fair and I think if you talk to the CEO of our SCB business, he would very simply say that I think, anything on ref gas, if you imagine a world scenario where you don't see China actively competing with you and you don't plan cost structures and an ability to compete at that level, you're never going to be effective.

I think we call this out even when we made the HFO announcement on the capex. I think the fact that we've developed our own non-infringing technology and the fact that it is what we believe going to be and I'm using the word loosely here, market-beating in terms of being cost competitive, should give you a good sense that we feel there's enough optimism to compete with anyone in the market.

I think that's going to be probably the one big question mark if any out there. Barring that, I think, and this got answered earlier today as well, it's a function I think of being able to entrench yourself with new product space, but with existing set of customers.

I think we've already demonstrated that capability and capacity for multiple years in the Western World already. I think it's just about leveraging a lot of the relationships.

I think we've done a phenomenal job of holding them through this whole period. I think we are a trusted partner with those businesses out of the Western World, and there's no reason to imagine that any of that should look differently merely because we've changed the grade of a product to something better, where I think the big daddies of that so-called product are curious to understand how SRF is going to impact it already.

I think all those signs augur very well in terms of being able to give us confidence to know that we are very well positioned to not just compete, but have access to the right markets when the products come on stream.

Sure, sir. Yeah.

Thank you, sir. Wish you all the best.

Thank you so much.

Thank you. The next question is from the line of Ranjit from IIFL Capital Services Limited.

Please go ahead.

Yeah. Thank you, sir.

Thanks for this opportunity. Thanks for sharing the strategic outlook.

I think it displays a clear intent of moving beyond agrochemicals. My first question is on the couple of comments that you have made in the presentation.

Firstly on the fluorochemicals, you have said that an aggressive expansion in the newer markets helps offset the softness in the US market. The question is that the aggression came at the cost of profitability and second, what's your outlook on the US market?

That would be my first question.

No, I don't think the market push was not at the cost of profitability. I think we've actually generated better price maybe in some of the newer markets we've gone into because they have some compelling needs, I think, even from a quota standpoint to make sure they're in a solid place as on the end of December.

I think they were just newer opportunities in areas that hitherto we've not kind of pushed product out into. We continue to explore those.

We see ourselves as being a global refrigerant player. Obviously, we will want to have a significant share in the key markets.

I think we also recognize the growing need to expand that global footprint into spaces where maybe there are opportunities that remain unaddressed. I think a lot of our effort kind of went over there.

US market, I think at this point, is buying very differently versus what it traditionally bought. Yes, to some extent it is softer, but it is also buying a very different product mix versus maybe the previous year.

I think that kind of trend is what's expected to continue. In some ways it plays out very well for us because I think a lot of other players are potentially going to struggle to be able to fulfill that demand that is coming out of the US.

As I see it, I think it's positioned SRF in a unique place because there aren't too many others who can go fulfill that demand very effectively at a meaningful scale, and the fact that any softness that we're seeing in the US is capacity that we can redirect elsewhere and address newer markets and grow them, just augurs very well, I think, in terms of the footprint for the future.

Sir, thank you. The second question is on the pharma pipeline.

I think we are seeing for the first time mentioning an encouraging traction in select molecules with key Western World customers. If you can shed bit more light on that and the potential revenues that we can generate.

What I can share is these are with two specific customers. They are very meaningful names in the pharmaceutical space.

With one of them, I think we should start seeing meaningful volume and revenue kind of start ticking through very quickly. This is in the larger oncological space in terms of a product.

The second one, unfortunately at this point is a lot less I can share, but yeah, suffice to say two very meaningful interactions that are looking very promising. If you recollect the last call, I had shared with you that we're engaged with more customers, and we're engaged on more molecules.

Hate saying it, but in a positive way, law of averages is playing out and I think that's translating into outcomes. Happy to have been able to call out the fact that on two of these we should start seeing positive momentum very quickly.

I am hoping that in the near term, I will be able to give you more constructive view in terms of revenue outlook and ramp and path. At this point in time, it's probably a little premature, Ranjit, but suffice to say in a very solid place on both those engagements and looking very promising in terms of what the revenue funnel could look like and as we kind of wrap.

Thank you, sir. The last one, you did call out the freight cost as one of the key elements for the drag in the margins.

If one way to put a ballpark figure for that, what it could be just on the percentage terms?

Depends on where you're shipping.

Seeing that most of Yeah.

Not all of it in all the cases. In some cases, yes, it is, but it's not everywhere.

If it was all passed through, I wouldn't have called that out as an impact. There are places where it isn't all being able to get pushed through to the customer in a sense, where pricing is a little bit more sensitive.

It's orders of magnitude, Ranjit, depending on where product is going out to. Choose a number 15%, 20% depending on where you're going to land product, in some cases are your numbers even higher than that.

It's a pretty wide range depending on where you're shipping and what route you're taking. Some of it is a function of the Middle East issue.

Some of it is just having to take longer routes to get to specific markets. It's a combination of factors, but yeah, there is definitely price inflation on that front.

I think that's across the board. It's not unique to us.

I think anyone who's exporting product out of India is kind of witnessing that. Even in our board meeting yesterday, we kind of heard that commentary through from some of the others who sit in the board in terms of what they were seeing in other businesses.

I think you want to hear that consistently from anyone who's an export-oriented kind of business in India today.

Fine, sir. Thank you for answering all the questions.

All right. Thanks, Ranjit.

Thank you. As there are no further questions from the participants, I now hand the conference over to the management for closing comments.

I hope we've been able to address your questions. Should you have any further queries, our team will be more than happy to assist.

We value your continued support and on behalf of the management team, thank you once again for taking the time to join us today. Bye-bye.

On behalf of DAM Capital Advisors Limited, that concludes this conference. Thank you for joining us and you may now disconnect your lines.